Uncategorised

The Royal College of Ophthalmologists (RCOphth) believes that ophthalmologists should have the discretion to prescribe Bevacizumab (Avastin) or alternatives such as Ranibizumab (Lucentis) or Aflibercept (Eylea), whichever is the most appropriate treatment of age related macular degeneration (AMD) for the patient, and provided the patient gives informed consent. The RCOphth has long petitioned a review

• 31 October 2017

Prescription patterns and the effectiveness of artificial tears in dry eye disease in the real world Victoria Nowak, Jelle Vehof, Daren Hanumunthadu   The DRy eye Outcome and Prescription Study (DROPS) is a large observational multicentre study exploring the ‘real world’ effectiveness of artificial tears in dry eye disease. Our aim is to include at

• 16 July 2017

Novel use of Nanopore-sequencing for Rapid Identification of Causative Pathogens and their Resistance Genes in Endophthalmitis (Nano-PoRE study) Liying Low Liying is currently a Fight for Sight Clinical Research Fellow in the Academic Unit of Ophthalmology, University of Birmingham and is on the steering committee of the West Midlands Deanery Ophthalmology Trainee Research Network. She

• 16 July 2017

The BMA Medical Academic Staff Committee (MASC) has developed a survey to help them gain a better understanding of what academic trainees do in the NHS to ensure that the protections in the 2016 junior doctor contract applies to them also. The survey has already been sent to academic trainees known to the BMA, but if you

• 1 June 2017

With the looming election on 8 June, it is an opportunity to outline our key policy calls for the next government to ensure that hospital eye services are adequately resourced. The two key areas are: Investment and recognition that development of a workforce to deliver high quality and timely care for patients is needed; with more ophthalmologists and

• 4 May 2017

• Tags | leaders in healthcare | manifesto | policy